|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2007-4-3
|
|
pubmed:abstractText |
A fully human monoclonal antibody to anti-alpha(v) integrins (CNTO 95) has been shown to inhibit angiogenesis and tumor growth in preclinical studies. We assessed the safety and pharmacokinetics of CNTO 95 in patients with advanced refractory solid tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BeckmanRobert ARA,
pubmed-author:BuonaccorsiGio AGA,
pubmed-author:CheungSueS,
pubmed-author:CorringhamRobert ERE,
pubmed-author:DaviesKarenK,
pubmed-author:DavisHugh MHM,
pubmed-author:HopeLynnL,
pubmed-author:JacksonAlanA,
pubmed-author:JaysonGordon CGC,
pubmed-author:JiaoQunQ,
pubmed-author:JulyanPeter JPJ,
pubmed-author:LangZhihuiZ,
pubmed-author:LawranceJeremyJ,
pubmed-author:MullamithaSaifee ASA,
pubmed-author:MunteanuMihaela CMC,
pubmed-author:NakadaMarian TMT,
pubmed-author:NemethJeffrey AJA,
pubmed-author:ParkerGeoff J MGJ,
pubmed-author:PrabhakarUmaU,
pubmed-author:RadfordJohn AJA,
pubmed-author:RobertsCalebC,
pubmed-author:SaundersMark PMP,
pubmed-author:TonNhuan CNC,
pubmed-author:ValleJuan WJW,
pubmed-author:WatsonYvonneY
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2128-35
|
|
pubmed:meshHeading |
pubmed-meshheading:17404096-Adult,
pubmed-meshheading:17404096-Aged,
pubmed-meshheading:17404096-Antibodies, Monoclonal,
pubmed-meshheading:17404096-Antineoplastic Agents,
pubmed-meshheading:17404096-Dose-Response Relationship, Drug,
pubmed-meshheading:17404096-Female,
pubmed-meshheading:17404096-Humans,
pubmed-meshheading:17404096-Immunohistochemistry,
pubmed-meshheading:17404096-Integrin alphaV,
pubmed-meshheading:17404096-Magnetic Resonance Imaging,
pubmed-meshheading:17404096-Male,
pubmed-meshheading:17404096-Maximum Tolerated Dose,
pubmed-meshheading:17404096-Middle Aged,
pubmed-meshheading:17404096-Neoplasms,
pubmed-meshheading:17404096-Positron-Emission Tomography,
pubmed-meshheading:17404096-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.
|
|
pubmed:affiliation |
Cancer Research, UK. Gordon.Jayson@christie-tr.nwest.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
